RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.
暂无分享,去创建一个
A. Aigner | U. Bakowsky | Sabrina Höbel | F. Czubayko | Marius Grzelinski | Tobias Martens | K. Lamszus | Beata Urban-Klein
[1] A. Aigner. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. , 2006, Journal of biotechnology.
[2] M. Sioud. RNA interference below the immune radar , 2006, Nature Biotechnology.
[3] M. Sioud. Single‐stranded small interfering RNA are more immunostimulatory than their double‐stranded counterparts: A central role for 2′‐hydroxyl uridines in immune responses , 2006, European journal of immunology.
[4] A. Aigner,et al. Ribozyme‐targeting reveals the rate‐limiting role of pleiotrophin in glioblastoma , 2005, International journal of cancer.
[5] S. Uprichard. The therapeutic potential of RNA interference , 2005, FEBS Letters.
[6] S. Nelson,et al. Differential Induction of Glioblastoma Migration and Growth by Two Forms of Pleiotrophin* , 2005, Journal of Biological Chemistry.
[7] C. Créminon,et al. Activation and Inhibition of Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase by Monoclonal Antibodies and Absence of Agonist Activity of Pleiotrophin* , 2005, Journal of Biological Chemistry.
[8] C. Ehrhardt,et al. Assessing transferrin modification of liposomes by atomic force microscopy and transmission electron microscopy. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[9] M. Sioud. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. , 2005 .
[10] A. Judge,et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA , 2005, Nature Biotechnology.
[11] J. Lieberman,et al. The prospect of silencing disease using RNA interference. , 2005, JAMA.
[12] A. Aigner,et al. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo , 2005, Gene Therapy.
[13] S. Akira,et al. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7 , 2005, Nature Medicine.
[14] A. Wellstein,et al. Ribozyme targeting of the growth factor pleiotrophin in established tumors: a gene therapy approach , 2005, Gene Therapy.
[15] C. Gondi,et al. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas , 2004, Oncogene.
[16] G. Hannon,et al. Unlocking the potential of the human genome with RNA interference , 2004, Nature.
[17] D. Fischer,et al. Effect of poly(ethylene imine) molecular weight and pegylation on organ distribution and pharmacokinetics of polyplexes with oligodeoxynucleotides in mice. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[18] A. Aigner,et al. Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. , 2004, Biochemical and biophysical research communications.
[19] E. Wagner,et al. Targeted nucleic acid delivery into tumors: new avenues for cancer therapy. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[20] A. Kichler. Gene transfer with modified polyethylenimines , 2004, The journal of gene medicine.
[21] K. Howard. Unlocking the money-making potential of RNAi , 2003, Nature Biotechnology.
[22] M. Westphal,et al. Expression and Function of the Receptor Protein Tyrosine Phosphatase ζ and Its Ligand Pleiotrophin in Human Astrocytomas , 2003, Journal of neuropathology and experimental neurology.
[23] M. Westphal,et al. A role for receptor tyrosine phosphataseζ in glioma cell migration , 2003, Oncogene.
[24] M. Westphal,et al. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] A. Heidenreich,et al. Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] D. Fischer,et al. Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression , 2002, Gene Therapy.
[27] L. Schomburg,et al. Effect of endotoxin on expression of TNF receptors and transport of TNF-alpha at the blood-brain barrier of the rat. , 2002, American journal of physiology. Endocrinology and metabolism.
[28] J. Held-Feindt,et al. Pleiotrophin, an angiogenic and mitogenic growth factor, is expressed in human gliomas , 2002, Journal of neurochemistry.
[29] A. Wellstein,et al. Anti-apoptotic Signaling of Pleiotrophin through Its Receptor, Anaplastic Lymphoma Kinase* , 2002, The Journal of Biological Chemistry.
[30] T. Muramatsu. Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. , 2002, Journal of biochemistry.
[31] C. Powers,et al. Pleiotrophin Signaling through Anaplastic Lymphoma Kinase Is Rate-limiting for Glioblastoma Growth* , 2002, The Journal of Biological Chemistry.
[32] T. Tuschl,et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.
[33] I. Zuhorn,et al. Lipoplex formation under equilibrium conditions reveals a three-step mechanism. , 2000, Biophysical journal.
[34] E. Holland,et al. Glioblastoma multiforme: the terminator. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[35] M. Herlyn,et al. An antisense strategy for inhibition of human melanoma growth targets the growth factor pleiotrophin. , 2000, Pigment cell research.
[36] G. Levi,et al. Size, diffusibility and transfection performance of linear PEI/DNA complexes in the mouse central nervous system , 1998, Gene Therapy.
[37] R. Jensen,et al. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. , 1998, Surgical neurology.
[38] S. Donnini,et al. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. , 1997, Cancer research.
[39] A. Wellstein,et al. Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[40] D. Scherman,et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[41] A. Wellstein,et al. Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer. , 1992, The Journal of biological chemistry.
[42] A. Wellstein,et al. A heparin-binding growth factor secreted from breast cancer cells homologous to a developmentally regulated cytokine. , 1992, The Journal of biological chemistry.
[43] J. Courty,et al. Mitogenic properties of a new endothelial cell growth factor related to pleiotrophin. , 1991, Biochemical and biophysical research communications.
[44] M. Watson,et al. Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity. , 1990, Science.
[45] R. Lupu,et al. Autocrine growth stimulation by secreted Kaposi fibroblast growth factor but not by endogenous basic fibroblast growth factor. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[46] T. Deuel,et al. A novel 17 kD heparin-binding growth factor (HBGF-8) in bovine uterus: purification and N-terminal amino acid sequence. , 1989, Biochemical and biophysical research communications.
[47] H. Rauvala. An 18‐kd heparin‐binding protein of developing brain that is distinct from fibroblast growth factors. , 1989, The EMBO journal.
[48] R. Schiffelers,et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. , 2004, Nucleic acids research.
[49] A. Wellstein,et al. Molecular and pharmacologic targeting of angiogenesis factors — the example of pleiotrophin , 2004, Breast Cancer Research and Treatment.
[50] M. Westphal,et al. Improved method for the intracerebral engraftment of tumour cells and intratumoural treatment using a guide screw system in mice , 2003, Acta Neurochirurgica.
[51] A. Wellstein,et al. Immunolocalization of an FGF-binding protein reveals a widespread expression pattern during different stages of mouse embryo development , 2001, Histochemistry and Cell Biology.
[52] T. Deuel,et al. Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors. , 1999, Current opinion in hematology.
[53] A. Wellstein,et al. Pleiotrophin and midkine in normal development and tumor biology. , 1995, Critical reviews in oncogenesis.
[54] M. Jaye,et al. Mitogenic and in vitro angiogenic activity of human recombinant heparin affin regulatory peptide. , 1994, Growth factors.